SCHEMBL986959

SCHEMBL986959

CCC(CC1CO1)[N+](C)(C)C

nearest known ligand 0.33

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 8/20 0.33
CHRM5 P08912 6/20 0.33
CHRM1 P11229 3/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
CHRM3 P20309 4/20 0.32
CHRM4 P08173 3/20 0.32
KDM4E B2RXH2 1/20 0.32
HTT P42858 1/20 0.32
ALDH1A1 P00352 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL475264 0.98 CHRM2 (0.32) CHRM2CHRM5CHRM1TSHRMAPK1
SCHEMBL472196 0.71
SCHEMBL51214 0.70
SCHEMBL52033 0.69
SCHEMBL6906542 0.68
SCHEMBL8816548 0.67
Water SCHEMBL5180865 0.67
SCHEMBL1148886 0.67
SCHEMBL28738879 0.67
SCHEMBL29245116 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105348575-A Formula of insulating cable jacket encapsulation WANG WEISONG 2016-02-24 CN claimed
JP-3931217-B2 2007-06-13 JP claimed
EP-0764174-B1 PROCESS FOR REMOVING BILE SALTS FROM A PATIENT AND ALKYLATED COMPOSITIONS THEREFOR GELTEX PHARMA INC (US) 1999-09-01 EP claimed
US-5917007-A Process for removing bile salts from a patient and alkylated compositions therefor GELTEX PHARMACEUTICALS, INC. (US) 1999-06-29 US claimed
EP-0909768-A2 Process for removing bile salts from a patient and alkylated compositions therefor GELTEX PHARMACEUTICALS, INC. (US) 1999-04-21 EP claimed
US-5693675-A Alkylated amine polymers GELTEX PHARMACEUTICALS INC. (US) 1997-12-02 US claimed
US-5679717-A Method for removing bile salts from a patient with alkylated amine polymers GELTEX PHARMACEUTICALS, INC. (US) 1997-10-21 US claimed
EP-0764174-A1 PROCESS FOR REMOVING BILE SALTS FROM A PATIENT AND ALKYLATED COMPOSITIONS THEREFOR GELTEX PHARMACEUTICALS, INC. (US) 1997-03-26 EP claimed
WO-1995034585-A1 PROCESS FOR REMOVING BILE SALTS FROM A PATIENT AND ALKYLATED COMPOSITIONS THEREFOR GELTEX PHARMACEUTICALS, INC. (US) 1995-12-21 WO claimed
US-6433026-B1 None US disclosed
US-10905711-B2 Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal VIFOR (INTERNATIONAL) LTD. (CH) 2021-02-02 US disclosed
US-20200085856-A1 ION BINDING POLYMERS AND USES THEREOF ILYPSA, INC. 2020-03-19 US disclosed
EP-3574896-A1 ION BINDING POLYMERS AND USES THEREOF Relypsa, Inc. (US) 2019-12-04 EP disclosed
US-10485821-B2 Ion binding polymers and uses thereof VIFOR (INTERNATIONAL) LTD. (CH) 2019-11-26 US disclosed
US-5679717-A Method for removing bile salts from a patient with alkylated amine polymers GELTEX PHARMACEUTICALS, INC. (US) 1997-10-21 US disclosed
US-5624963-A Process for removing bile salts from a patient and compositions therefor GELTEX PHARMACEUTICALS, INC. (US) 1997-04-29 US disclosed
EP-0764174-A1 PROCESS FOR REMOVING BILE SALTS FROM A PATIENT AND ALKYLATED COMPOSITIONS THEREFOR GELTEX PHARMACEUTICALS, INC. (US) 1997-03-26 EP disclosed
EP-0764177-A1 CROSS-LINKED POLYMERS FOR REMOVING BILE SALTS FROM A PATIENT GELTEX PHARMACEUTICALS, INC. (US) 1997-03-26 EP disclosed
WO-1995034588-A1 CROSS-LINKED POLYMERS FOR REMOVING BILE SALTS FROM A PATIENT GELTEX PHARMACEUTICALS, INC. (US) 1995-12-21 WO disclosed
WO-1995034585-A1 PROCESS FOR REMOVING BILE SALTS FROM A PATIENT AND ALKYLATED COMPOSITIONS THEREFOR GELTEX PHARMACEUTICALS, INC. (US) 1995-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10905711-B2 Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal KCNN3, KCNH3, KCNH2 CHRM2 2181/4885CHRM5 1461/4885CHRM1 2808/4885
US-20200085856-A1 ION BINDING POLYMERS AND USES THEREOF ATP6V1B1, KCNN3, SLC9A3 CHRM2 4389/4885CHRM5 3565/4885CHRM1 4647/4885
US-10485821-B2 Ion binding polymers and uses thereof ATP6V1B1, KCNN3, SLC9A3 CHRM2 4389/4885CHRM5 3565/4885CHRM1 4647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.